Tien Hsien Liquid is an Immunotherapy treatment which has the immune system fight off the infection or disease. It is used as a dietary supplement to help strengthen the body's immune system. In turn, the immune system then identifies, attacks and destroys tumorous or cancerous cells.

 

Published Medical Research

Tien Hsien Research Study Published in American Journal of Chinese Medicine

Title: Immunomodulating Effects of "Tien-Hsien Liquid" on Peripheral Blood Mononuclear Cells and T-Lymphocytes from Patients with Recurrent Aphthous Ulcerations

Source: The American Journal of Chinese Medicine, Vol. 32, No. 2 (2004) 221-234

Copyright: World Scientific Publishing Company & Institute for Advanced Research in Asian Science and Medicine
Author(s): Andy Sun
Institute of Microbiology, College of Medicine, National Taiwan University, ROC

Jean-San Chia
Institute of Microbiology, College of Medicine, National Taiwan University, ROC

Won-Bo Wang
Institute of Microbiology, College of Medicine, National Taiwan University, ROC

Abstract: Recurrent aphthous ulcerations (RAU) represent a common oral mucosal disease with altered humoral and cellular immunities. In our institution, an immunomodulating agent, levamisole, is used to treat RAU with satisfactory therapeutic effect. Tien-Hsien liquid (THL) is an extract of Chinese medicinal herbs with immunomodulating effects. To test whether THL has immunomodulating effects on antigen-stimulated proliferation response (PR) of peripheral blood mononuclear cells (PBMC) and T-cells isolated from RAU patients and to test whether THL is a potential drug for treating RAU, PBMC or T-cells isolated from RAU patients were incubated with lipopolysaccharides (LPS) from Escherica coli, phytohemagglutinin (PHA), staphylococcal enterotoxin B (SEB), glutaraldehyde-inactivated tetanus toxoid (TT), glucosyltransferase D (GtfD), or antigens of Streptococcus mutans in the presence or absence of THL. We found that THL significantly increased the LPS-stimulated PR of PBMC from active RAU patients, the GtfD-stimulated PR of PBMC and of T-cells from inactive RAU patients, and the S. mutans-stimulated PR of PBMC from inactive RAU patients. However, THL could also significantly reduce the SEB-stimulated PR of PBMC and of T-cells from active RAU patients and S. mutans-stimulated PR of T-cells from active RAU patients. These results suggest that THL can modulate the antigen-stimulated PR of PBMC and T-cells from RAU patients. Therefore, it may be a potential immunoceutical agent for treatment of RAU.
 


Tien Hsien Research Study Published in Evidence-Based Complementary and Alternative Medicine

Title: Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial
Source: Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 803239, 8 pages
doi:10.1155/2012/803239
Copyright: Copyright 2012 Wen-Hung Kuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Author(s): Wen-Hung Kuo
Department of General Surgery, National Taiwan University Hospital, Taipi, Taiwan

Chien-An Yao
Department of Family Medicine, National Taiwan University Hospital, Taipi, Taiwan

Chih Hui Lin
Gerent Biotech Co., Ltd., Taichung, Taiwan

King-Jen Chang
Department of General Surgery, National Taiwan University Hospital, Taipi, Taiwan
Department of Surgery, Cheng Ching General Hospital, Taichung, Taiwan

Abstract: To evaluate the safety and efficacy of Tien-Hsien Liquid Practical (THL-P), a Chinese herbal mixture, in patients with refractory metastatic breast cancer, we performed a randomized, double-blind, placebo-controlled, parallel-group, phase IIa pilot trial. Patients were randomly assigned to either receive THL-P or matching placebo and followed up every 4 weeks for 24 weeks. The primary endpoint was changes in the global health status/quality of life (GHS/QOL) scale. The secondary endpoints were changes in functional and symptom scales, immunomodulating effects, and adverse events. Sixty-three patients were enrolled between June 2009 and June 2011. The intent-to-treat population included 28 patients in the THL-P group and 11 patients in the placebo group. Compared to the placebo group, the THL-P group had significant improvement from baseline to last visit in GHS/QOL (41.7 versus −33.3; , ), CD3, CD4/CD8, CD19, CD16+56 positive cells (, ), and higher levels of physical, role, emotional, and cognitive functioning, as well as decreased fatigue and systemic side effects. Treatment-related adverse events were mild constipation and localized itching, and no serious adverse events were reported. THL-P appears to be a safe alternative adjuvant treatment for patients with refractory metastatic breast cancer, as it effectively improves QOL and palliates cancer-related symptoms.
 

Awards and Recognition (Dr. Wang Zhen Guo - formulator of Tien Hsien)

Dr. Wang Zhen Guo (left) is in the First Annual Ten Best Youths of China awards. (1990)

Medaille De Chevalier*

Diplome D'Officier*

Diplome De Chevalier*

Diplome Du Merite De L'invention*

*Awarded in the 38th World Fair for Invention, Research and Industrial Innovation held in Brussels.

1989 - Best Individual Invention at the 38th Brussels Eureka World Fair for Invention.  (1) Medal for Honor by the King of Belgium. (2) General Medal by the King of Belgium. (3) Knights Medal by the King of Belgium.

1990 - Recipient of the Second Annual Technology Entrepreneurs Award in China

1990 - Recipient of the National Distinguished Contribution Award  for Outstanding Young Professional

1991 - Recipient of the National Outstanding Achievement Award for Self-Proficiency

1992- Community Excellence Award for Technology Entrepreneur in China 

1992 - Recognized by China as an Outstanding Intelligent National

1992 - Became the First Chinese Traditional Doctor Recorded in the Who's Who of Intellectuals by the International Biographical Center at Cambridge, England.

1995 - National Crucial New Product of the Year Award - Tien Hsien Liquid No. 1

1997 - Only Chinese Pharmacologist invited to lecture at the Third Annual Japan Cancer Expo conducted by the American Cancer Control Association.

1998 - Published the latest in Anti-Cancer Research and Developments in the Fourth Annual Japan Cancer Expo conducted by the American Cancer Control Association